GLUE Strangle Strategy

GLUE (Monte Rosa Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

GLUE (Monte Rosa Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.23B, a beta of 1.62 versus the broader market, a 52-week range of 3.51-25.77, average daily share volume of 1.0M, a public-listing history dating back to 2021, approximately 142 full-time employees. These structural characteristics shape how GLUE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.62 indicates GLUE has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on GLUE?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current GLUE snapshot

As of May 15, 2026, spot at $18.13, ATM IV 106.10%, IV rank 43.63%, expected move 30.42%. The strangle on GLUE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on GLUE specifically: GLUE IV at 106.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 30.42% (roughly $5.51 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated GLUE expiries trade a higher absolute premium for lower per-day decay. Position sizing on GLUE should anchor to the underlying notional of $18.13 per share and to the trader's directional view on GLUE stock.

GLUE strangle setup

The GLUE strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With GLUE near $18.13, the first option leg uses a $19.04 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed GLUE chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 GLUE shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$19.04N/A
Buy 1Put$17.22N/A

GLUE strangle risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

GLUE strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on GLUE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on GLUE

Strangles on GLUE are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GLUE chain.

GLUE thesis for this strangle

The market-implied 1-standard-deviation range for GLUE extends from approximately $12.62 on the downside to $23.64 on the upside. A GLUE long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current GLUE IV rank near 43.63% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on GLUE should anchor more to the directional view and the expected-move geometry. As a Healthcare name, GLUE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to GLUE-specific events.

GLUE strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. GLUE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move GLUE alongside the broader basket even when GLUE-specific fundamentals are unchanged. Always rebuild the position from current GLUE chain quotes before placing a trade.

Frequently asked questions

What is a strangle on GLUE?
A strangle on GLUE is the strangle strategy applied to GLUE (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With GLUE stock trading near $18.13, the strikes shown on this page are snapped to the nearest listed GLUE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are GLUE strangle max profit and max loss calculated?
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the GLUE strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 106.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a GLUE strangle?
The breakeven for the GLUE strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current GLUE market-implied 1-standard-deviation expected move is approximately 30.42%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on GLUE?
Strangles on GLUE are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GLUE chain.
How does current GLUE implied volatility affect this strangle?
GLUE ATM IV is at 106.10% with IV rank near 43.63%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related GLUE analysis